Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
50% Effective Dose of Dexmedetomidine for General Anesthesia Induction
ChiCTR2100046916Phase 4Recruiting
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dexmedetomidine in cancer and None, sponsored by Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoint: 50% effective dose of dexmedetomidine (ED50). Started Jun 2021; status: recruiting.
02
Drugs
dexmedetomidine
03
Conditions
cancer
Beyond the preview
Go deeper on ChiCTR2100046916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046916.